Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

s and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... - The Fight Against Cancer Innovation Trust (FACIT) ... formation of Turnstone Biologics Inc. (Turnstone), a biotechnology ... harness the patient,s own immune system. ... Children,s Hospital of Eastern Ontario ... Institute for Cancer Research (OICR), the Ottawa Hospital ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Genedata, ... drug discovery and life science research, today announced ... the latest version of its enterprise solution for ... R&D enables more efficient discovery and development of ... to integrate and address protein optimization and developability ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) ... products that address unmet medical needs in the areas ... will be presenting preclinical data from three of its ... Science and Technology Conference on May 12-14, 2015 to ... 701 Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... 4, 2015 - New Massive ... students prepare for the United States Medical Licensing Examination ... scientific, technical and medical information products and services, announced ... Open Online Course) designed to help medical students prepare ... 1, the first and most daunting of the three ...
Breaking Biology Technology:Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3
... Here are some troubleshooting hints that we have gathered , if your PCR yields no product:, , , ... , , , ... , , , ... , , , ...
... , , , , , Here are some troubleshooting hints that we have gathered , ... , , , ... , , , ... , , , , ...
... , , , , from rat lung, recombinant, , , , ... Catalog Number, Pack Size, , ... , , 3335402, ... , , , , , Package Inserts/Product , Instructions, ...
Cached Biology Technology:Trouble-shooting: No product 2Trouble-shooting: No product 3Trouble-shooting: No product 4Trouble-shooting: No product 5Trouble-shooting: Non-specific bands 2Trouble-shooting: Non-specific bands 3Trouble-shooting: Non-specific bands 4Trouble-shooting: Non-specific bands 5Trouble-shooting: Non-specific bands 6
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... , This release is available in German ... area of climate research: for decades, scientists have been asking ... dust particles suspended in the atmosphere, enlarge the cloud cover ... no progress on this issue. Two scientists from the Max ...
... a major milestone in its three years of operation, RadMD ... for 150 clinical trials. , The most recent trial, ... was designed to test the efficacy of a new treatment ... support the primary analysis of Progression Free Survival based on ...
... scientists have received grants from the latest round of ... Recovery and Reinvestment Act (ARRA) of 2009. To date, ... million. The recent round of funding includes three highly ... the Challenge Grant competition ― only about 500 were ...
Cached Biology News:Do dust particles curb climate change? 2Do dust particles curb climate change? 3Do dust particles curb climate change? 4RadMD reaches 150th clinical trial 2Forsyth receives highly competitive challenge grants 2
... 5 ml. The same high performance ... columns for fast, reliable purification of ... 5/50 GL, XK 16/20, or other ... required.Extremely useful for exploiting either the ...
Luminometers...
...
... 200 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
Biology Products: